Analyst Price Target Update on Laboratory Corporation of America Holdings (NYSE:LH)

Laboratory Corporation of America Holdings (NYSE:LH) should head towards $141.5 per share according to 14 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $125 per share. The higher price estimate target is at $160 according to the Analysts.

Many analysts have stated their opinion on the company shares. Barclays maintains its view on Laboratory Corporation of America Holdings (NYSE:LH) according to the research report released by the firm to its investors. The shares have now been rated Overweight by the stock experts at the ratings house. Barclays raises the price target from $152 per share to $155 per share on Laboratory Corporation of America Holdings. The rating by the firm was issued on April 26, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Chief Human Resources Officer) of Laboratory Corp Of America Holdings, Uthgenannt Lisa J had sold 3,740 shares worth of $468,136 in a transaction dated April 29, 2016. In this transaction, 3,740 shares were sold at $125.17 per share.

Laboratory Corporation of America Holdings (NYSE:LH) stock ended Monday session in the red zone in a volatile trading. The stock closed down 2.76 points or 2.12% at $127.54 with 1,159,900 shares getting traded. Post opening the session at $129.48, the shares hit an intraday low of $127.36 and an intraday high of $130.13 and the price was in this range throughout the day. The company has a market cap of $13,060 million and the number of outstanding shares have been calculated to be 102,400,000 shares. The 52-week high of Laboratory Corporation of America Holdings (NYSE:LH) is $131.99 and the 52-week low is $97.79.

Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment, which includes core testing, as well as genomic and esoteric testing; and the Other segment, which consists of the Companys non-United States clinical diagnostic laboratory operations in Ontario, Canada. It also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, womens health, cardiovascular disease, identity, forensics, infectious disease, endocrinology, oncology, coagulation, occupational testing and pain management.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.